HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.

Singer CF, Jahn SW, Hlauschek D, Heber UM, Mang-Manger C, Egle D, Balic M, Pichler A, Pfeiler G, Kacerovsky-Strobl S, Suppan C, Ritter M, Petru E, Greil R, Bago-Horvath Z, Deutschmann C, Steger GG, Seifert M, Fitzal F, Bartsch R, Santhanagopal A, Machacek-Link J, Sellami D, Schwarz M, Fesl C, Sölkner L, Esker S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Cancer Commun (Lond). 2025 Jan 6. doi: 10.1002/cac2.12657. Online ahead of print. PMID: 39757921 No abstract available.

https://pubmed.ncbi.nlm.nih.gov/39757921/